JY-017

N/A

Report date: 2025/10/09 20:00:09

Base Information

Drug NameJY-017

Drug Alias NameCD123+CLL-1 Dual-target CAR-T Cells therapy (Institute Of Hematology & Blood Diseases Hospital)JY017JY-017

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-3 receptor subunit alpha modulatorsC-Type lectin domain family 12 member A modulatorsT lymphocyte replacements

TargetsInterleukin-3 receptor subunit alphaC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A